文献速递肝病消化道肿瘤与早癌

基因组医学及其对肝细胞癌预防和治疗的启示

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.
PubMed 文献 · Gastroenterology · 2018-11-04

综述基因组学进展如何增进对乙肝病毒、丙肝病毒、酒精、脂肪肝病及黄曲霉毒素等环境因素致肝癌机制的理解,并讨论基因分析对肿瘤起始与进展的提示、个体化管理潜力,以及索拉非尼以外多激酶抑制剂和免疫治疗的初步成功。

要点

  • 基因组学进展增进了对乙肝病毒、丙肝病毒、酒精、脂肪肝病及黄曲霉毒素等致肝癌机制的理解。
  • 对患者肝组织的基因分析提供了肿瘤起始和进展的重要信息,可能用于肝细胞癌的个体化管理。
  • 除索拉非尼外,其他多激酶抑制剂近期已获批用于肝细胞癌治疗,免疫治疗的初步成功带来希望。

核心结论

  • 基因组医学的持续进展可能改善基于分子特征的肝细胞癌分类,并为肝癌患者带来新治疗。

研究设计与样本

  • 综述,围绕肝细胞癌基因组医学进展及其对预防和治疗的启示展开论述。

主要发现

  • 对患者肝组织的基因分析提供了肿瘤起始和进展的重要信息。
  • 除索拉非尼外,其他多激酶抑制剂近期已获批用于肝细胞癌治疗。
  • 免疫治疗的初步成功提高了希望。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent advances in genomics have increased our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease, and other environmental factors, such as aflatoxin, cause liver cancer. Genetic analyses of liver tissues from patients have provided important information about tumor initiation and progression. Findings from these studies can potentially be used to individualize the management of HCC. In addition to sorafenib, other multi-kinase inhibitors have been approved recently for treatment of HCC, and the preliminary success of immunotherapy has raised hopes. Continued progress in genomic medicine could improve classification of HCCs based on their molecular features and lead to new treatments for patients with liver cancer.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Dhanasekaran R, Nault JC, Roberts LR, et al. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology. 2018. PMID: 30404026. doi:10.1053/j.gastro.2018.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。